‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Kyle LaHucik

Senior Reporter

Antiva Biosciences has picked up another $53 million to bankroll two key studies of its topical drug for high-risk HPV infections and pre-cancerous lesions. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal

‘Sleep­ing block­buster’: MPM leads $53M Se­ries E for An­ti­va as biotech seeks sec­ond go at tack­ling HPV

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

‘Sleeping blockbuster’: MPM leads $53M Series E for Antiva as biotech seeks second go at tackling HPV

WuXi AppTec will sell cell and gene therapy business to private equity firm

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

CMS explains what went into its first round of drug price negotiations

PDUFAs for Tonix and Nuvation; Sanofi vaccine partnership; RAPT allergy deal